Tobias S. Köhler MD , Robert A. Kloner MD, PhD , Raymond C. Rosen PhD , Arthur L. Burnett MD, MBA , Michael J. Blaha MD , Peter Ganz MD , Irwin Goldstein MD , Noel N. Kim PhD , Tom Lue MD, ScD , Kevin T. McVary MD , John P. Mulhall MD, MSc , Sharon J. Parish MD , Hossein Sadeghi-Nejad MD , Richard Sadovsky MD , Ira D. Sharlip MD , Martin Miner MD
{"title":"普林斯顿第四届勃起功能障碍和心血管疾病管理共识建议》。","authors":"Tobias S. Köhler MD , Robert A. Kloner MD, PhD , Raymond C. Rosen PhD , Arthur L. Burnett MD, MBA , Michael J. Blaha MD , Peter Ganz MD , Irwin Goldstein MD , Noel N. Kim PhD , Tom Lue MD, ScD , Kevin T. McVary MD , John P. Mulhall MD, MSc , Sharon J. Parish MD , Hossein Sadeghi-Nejad MD , Richard Sadovsky MD , Ira D. Sharlip MD , Martin Miner MD","doi":"10.1016/j.mayocp.2024.06.002","DOIUrl":null,"url":null,"abstract":"<div><p>The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative symposium dedicated to optimizing sexual function and preserving cardiovascular health. The Fourth Princeton Consensus Conference was convened on March 10-11, 2023, at the Huntington Medical Research Institutes in Pasadena, California. Princeton panels I to III addressed the clinical management of men with erectile dysfunction (ED) who also had cardiovascular disease. Thirteen years since Princeton III, Princeton IV builds on previous foundations in several key areas. Mounting evidence supports the need for providers to treat men with ED as being at risk for cardiac events until proven otherwise. Algorithms for the diagnosis and treatment of ED are updated with new recommendations for coronary artery calcium scoring for advanced cardiovascular risk stratification. Optimization of oral phosphodiesterase type 5 inhibitors in the treatment of men with ED and cardiovascular disease is thoroughly explored, including recent evidence of potential cardioprotective effects of these drugs.</p></div>","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":"99 9","pages":"Pages 1500-1517"},"PeriodicalIF":6.9000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0025619624002763/pdfft?md5=41d6a2428b6fbd62dc40a04ec3cf465a&pid=1-s2.0-S0025619624002763-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The Princeton IV Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease\",\"authors\":\"Tobias S. Köhler MD , Robert A. Kloner MD, PhD , Raymond C. Rosen PhD , Arthur L. Burnett MD, MBA , Michael J. Blaha MD , Peter Ganz MD , Irwin Goldstein MD , Noel N. Kim PhD , Tom Lue MD, ScD , Kevin T. McVary MD , John P. Mulhall MD, MSc , Sharon J. Parish MD , Hossein Sadeghi-Nejad MD , Richard Sadovsky MD , Ira D. Sharlip MD , Martin Miner MD\",\"doi\":\"10.1016/j.mayocp.2024.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative symposium dedicated to optimizing sexual function and preserving cardiovascular health. The Fourth Princeton Consensus Conference was convened on March 10-11, 2023, at the Huntington Medical Research Institutes in Pasadena, California. Princeton panels I to III addressed the clinical management of men with erectile dysfunction (ED) who also had cardiovascular disease. Thirteen years since Princeton III, Princeton IV builds on previous foundations in several key areas. Mounting evidence supports the need for providers to treat men with ED as being at risk for cardiac events until proven otherwise. Algorithms for the diagnosis and treatment of ED are updated with new recommendations for coronary artery calcium scoring for advanced cardiovascular risk stratification. Optimization of oral phosphodiesterase type 5 inhibitors in the treatment of men with ED and cardiovascular disease is thoroughly explored, including recent evidence of potential cardioprotective effects of these drugs.</p></div>\",\"PeriodicalId\":18334,\"journal\":{\"name\":\"Mayo Clinic proceedings\",\"volume\":\"99 9\",\"pages\":\"Pages 1500-1517\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0025619624002763/pdfft?md5=41d6a2428b6fbd62dc40a04ec3cf465a&pid=1-s2.0-S0025619624002763-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mayo Clinic proceedings\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0025619624002763\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mayo Clinic proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0025619624002763","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
普林斯顿共识（专家小组）会议是一个致力于优化性功能和保护心血管健康的多专业合作研讨会。第四次普林斯顿共识会议于 2023 年 3 月 10-11 日在加利福尼亚州帕萨迪纳的亨廷顿医学研究所召开。普林斯顿第一至第三小组讨论了患有心血管疾病的男性勃起功能障碍（ED）患者的临床治疗问题。自普林斯顿会议三以来，普林斯顿会议四已经过去了十三年。越来越多的证据表明，医疗服务提供者有必要将患有 ED 的男性视为有心脏事件风险的患者，直到事实证明并非如此。更新了诊断和治疗 ED 的算法，并提出了冠状动脉钙化评分的新建议，以进行高级心血管风险分层。深入探讨了口服5型磷酸二酯酶抑制剂在治疗男性ED和心血管疾病中的优化作用，包括这些药物潜在的心脏保护作用的最新证据。
The Princeton IV Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative symposium dedicated to optimizing sexual function and preserving cardiovascular health. The Fourth Princeton Consensus Conference was convened on March 10-11, 2023, at the Huntington Medical Research Institutes in Pasadena, California. Princeton panels I to III addressed the clinical management of men with erectile dysfunction (ED) who also had cardiovascular disease. Thirteen years since Princeton III, Princeton IV builds on previous foundations in several key areas. Mounting evidence supports the need for providers to treat men with ED as being at risk for cardiac events until proven otherwise. Algorithms for the diagnosis and treatment of ED are updated with new recommendations for coronary artery calcium scoring for advanced cardiovascular risk stratification. Optimization of oral phosphodiesterase type 5 inhibitors in the treatment of men with ED and cardiovascular disease is thoroughly explored, including recent evidence of potential cardioprotective effects of these drugs.
期刊介绍：
Mayo Clinic Proceedings is a premier peer-reviewed clinical journal in general medicine. Sponsored by Mayo Clinic, it is one of the most widely read and highly cited scientific publications for physicians. Since 1926, Mayo Clinic Proceedings has continuously published articles that focus on clinical medicine and support the professional and educational needs of its readers. The journal welcomes submissions from authors worldwide and includes Nobel-prize-winning research in its content. With an Impact Factor of 8.9, Mayo Clinic Proceedings is ranked #20 out of 167 journals in the Medicine, General and Internal category, placing it in the top 12% of these journals. It invites manuscripts on clinical and laboratory medicine, health care policy and economics, medical education and ethics, and related topics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
